Rocket Pharmaceuticals Aktie
WKN DE: A2JA9Q / ISIN: US77313F1066
|
30.06.2025 13:23:06
|
Rocket Pharma Gets FDA IND Clearance Of RP-A701 In BAG3-associated Dilated Cardiomyopathy
(RTTNews) - Rocket Pharmaceuticals, Inc. (RCKT) Monday said that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for RP-A701, its gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM)
BAG3-DCM is a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.
"Phase 1 trial start-up activities are currently underway for RP-A701, and we are working towards treating the first patient," said Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharma.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Rocket Pharmaceuticalsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Rocket Pharmaceuticalsmehr Analysen
Aktien in diesem Artikel
| Rocket Pharmaceuticals | 3,27 | 2,48% |
|